GLUCOTRACK INC (GCTK)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.98-10.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · GCTK
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance and launch the U.S. clinical trial for the fully implantable continuous blood glucose monitoring system in the second half of 2026.
Newly stated in 2026-Q1. Management submitted an IDE application to the FDA and targets initiating the U.S. clinical trial in the second half of 2026. Financials show ongoing net losses and negative operating income, consistent with a development-stage company advancing clinical programs. The trajectory is consistent with management's stated plan to initiate clinical studies shortly after early Q3 2026.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Successfully submitted IDE application to FDA to initiate U.S. clinical study for fully implantable CBGM technology.”
Finalize the acquisition and integrate Lōkahi Therapeutics to expand biopharmaceutical platform capabilities.
Stated in 2 recent quarters. Management operates Lōkahi Therapeutics as a strategic biopharmaceutical platform and secured $5.5 million in financing in 2026-Q3 to support its development. Financials show continued net losses and negative operating income, reflecting ongoing investment. The trajectory shows active capital raising and integration efforts consistent with stated priorities.
“Glucotrack operates Lōkahi Therapeutics, a biopharmaceutical platform focused on advancing therapeutic opportunities.”
“Announced $5.5 million financing to support Lōkahi Therapeutics and growth capital.”
Improve balance sheet strength through debt reduction, equity financing, and capital management to extend operational runway.
Stated in 3 of last 3 quarters. Management reduced promissory note balance from $3.6M to $1.6M by 2026-Q1, drew $1.0M on equity line of credit in 2026-Q2, and completed $5.5M financing in 2026-Q3. Cash decreased from $7.4M at end 2025 to $3.9M at 2026-Q1, reflecting cash used in operations. The trajectory shows active capital management and financing efforts to extend runway, consistent with stated priorities.
“Announced $5.5 million financing including equity and convertible debt to strengthen balance sheet.”
“Drew approximately $1.0 million under equity line of credit, reducing promissory note balance.”
“Reduced outstanding promissory note balance from $3.6M to $1.6M through exchange into common stock.”
Continue publishing scientific and clinical data in peer-reviewed journals to validate implantable CBGM technology.
Newly stated in 2026-Q1. Management published two peer-reviewed articles demonstrating long-term sensor stability and accuracy with a 6.8% MARD over 240 days in an ovine model. This supports the product development and clinical validation efforts. The trajectory shows initial scientific validation consistent with management's stated research priorities.
“Published peer-reviewed articles in IEEE Sensors Journal and The Journal of Diabetes Research supporting CBGM technology.”
Execute a reverse stock split to comply with Nasdaq minimum bid price requirements and maintain listing status.
Newly stated in 2026-Q3. Management announced a 1-for-15 reverse stock split effective August 31, 2026 to comply with Nasdaq's $1.00 minimum bid price requirement and maintain listing. This is a regulatory compliance action with no direct financial impact reported yet. The trajectory is consistent with addressing listing standards.
Over the trailing year it converted 0.75x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
34 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.